NYSE:MNK - Mallinckrodt Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$20.63 +0.73 (+3.67 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$20.63
Today's Range$19.75 - $20.65
52-Week Range$11.65 - $36.65
Volume1.32 million shs
Average Volume2.05 million shs
Market Capitalization$1.66 billion
P/E Ratio2.75
Dividend YieldN/A
Beta1.9
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as proteinuria, multiple sclerosis, infantile spasms, ophthalmic, neuromuscular disorders, dermatomyositis, polymyositis, rheumatology, and pulmonology; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; Therakos, an immunotherapy treatment platform; and Amitiza for the treatment of chronic idiopathic constipation. The company is also developing StrataGraft, which is in Phase III and II clinical development for the treatment of burns; terlipressin for the treatment of hepatorenal syndrome; MNK-1411 for the treatment of Duchenne muscular dystrophy; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative fatal disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. Mallinckrodt public limited company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company is based in Staines-Upon-Thames, the United Kingdom.

Receive MNK News and Ratings via Email

Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-0-17-8463-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.22 billion
Cash Flow$16.7724 per share
Book Value$68.65 per share

Profitability

Net Income$2.13 billion

Miscellaneous

Employees3,900
Market Cap$1.66 billion
OptionableOptionable

Mallinckrodt (NYSE:MNK) Frequently Asked Questions

What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

How will Mallinckrodt's stock buyback program work?

Mallinckrodt declared that its Board of Directors has authorized a share buyback plan on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to buy up to 18.5% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's leadership believes its shares are undervalued.

How were Mallinckrodt's earnings last quarter?

Mallinckrodt PLC (NYSE:MNK) announced its quarterly earnings data on Tuesday, November, 6th. The company reported $2.10 earnings per share for the quarter, beating analysts' consensus estimates of $1.79 by $0.31. The company earned $640 million during the quarter, compared to analysts' expectations of $634.38 million. Mallinckrodt had a net margin of 65.24% and a return on equity of 9.60%. The firm's revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.97 EPS. View Mallinckrodt's Earnings History.

When is Mallinckrodt's next earnings date?

Mallinckrodt is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Mallinckrodt.

How can I listen to Mallinckrodt's earnings call?

Mallinckrodt will be holding an earnings conference call on Tuesday, February 26th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8773599508.

What guidance has Mallinckrodt issued on next quarter's earnings?

Mallinckrodt issued an update on its FY18 earnings guidance on Tuesday, November, 6th. The company provided earnings per share guidance of $7.00-7.20 for the period, compared to the Thomson Reuters consensus estimate of $6.75. Mallinckrodt also updated its FY 2018 guidance to $7.00-7.20 EPS.

What price target have analysts set for MNK?

16 analysts have issued 12 month target prices for Mallinckrodt's stock. Their forecasts range from $20.00 to $58.00. On average, they anticipate Mallinckrodt's share price to reach $32.5333 in the next year. This suggests a possible upside of 57.7% from the stock's current price. View Analyst Price Targets for Mallinckrodt.

What is the consensus analysts' recommendation for Mallinckrodt?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 3 sell ratings, 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mallinckrodt.

What are Wall Street analysts saying about Mallinckrodt stock?

Here are some recent quotes from research analysts about Mallinckrodt stock:
  • 1. According to Zacks Investment Research, "Mallinckrodt’s hospital franchise (Inomax and Ofirmev) has gained traction which is positively impacting performance. The spin-off of the generic business appears to be a step in the right direction as this will enable Mallinckrodt to focus better on the branded business, which promises potential. Mallinckrodt has streamlined its business of late to focus better on its innovative medicines and therapies. The company has been involved in quite a few lawsuits for its alleged role in the current opioid epidemic in the United States through its marketing and promotion practices. Shares have outperformed the industry in the last six months. However, pipeline setbacks continue to weigh on the company. The CRL for stannsoporfin was disappointing. Acthar, Mallinckrodt’s largest product, is being impacted by the residual impact of the previously reported patient withdrawal issues." (1/8/2019)
  • 2. Mizuho analysts commented, "We reiterate our Neutral rating into what we view as risky read-outs for VTS-270 in Niemann- Pick Type C, and CPP-1X/Sulindac in FAP." (11/6/2018)
  • 3. Canaccord Genuity analysts commented, "We were pleasantly surprised by Mallinckrodt’s 2Q/18 beat and raise last week as the story continues to evolve toward higher pipeline science and away from Acthar- related drama. However, with strong momentum behind MNK shares of late, we remain concerned about external forces on Acthar or internal pipeline setbacks potentially squelching momentum in the story." (8/13/2018)

Has Mallinckrodt been receiving favorable news coverage?

Media stories about MNK stock have been trending somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Mallinckrodt earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the near term.

Who are some of Mallinckrodt's key competitors?

Who are Mallinckrodt's key executives?

Mallinckrodt's management team includes the folowing people:
  • Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 58)
  • Dr. Frank Scholz, Exec. VP and Chief Operations & Digital Innovation Officer (Age 50)
  • Mr. Matthew K. Harbaugh, Exec. VP & Pres of the Specialty Generics Bus. (Age 49)
  • Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial Officer (Age 56)
  • Mr. George A. Kegler Jr., Exec. VP & CFO (Age 63)

Who are Mallinckrodt's major shareholders?

Mallinckrodt's stock is owned by a number of of retail and institutional investors. Top institutional investors include Dorsey Wright & Associates (0.18%), Meeder Asset Management Inc. (0.05%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own Mallinckrodt stock include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, James E Flynn, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Institutional Ownership Trends for Mallinckrodt.

Which institutional investors are selling Mallinckrodt stock?

MNK stock was sold by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc. and Louisiana State Employees Retirement System. View Insider Buying and Selling for Mallinckrodt.

Which institutional investors are buying Mallinckrodt stock?

MNK stock was purchased by a variety of institutional investors in the last quarter, including Dorsey Wright & Associates. Company insiders that have bought Mallinckrodt stock in the last two years include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Insider Buying and Selling for Mallinckrodt.

How do I buy shares of Mallinckrodt?

Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mallinckrodt's stock price today?

One share of MNK stock can currently be purchased for approximately $20.63.

How big of a company is Mallinckrodt?

Mallinckrodt has a market capitalization of $1.66 billion and generates $3.22 billion in revenue each year. The company earns $2.13 billion in net income (profit) each year or $7.49 on an earnings per share basis. Mallinckrodt employs 3,900 workers across the globe.

What is Mallinckrodt's official website?

The official website for Mallinckrodt is http://www.mallinckrodt.com.

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]


MarketBeat Community Rating for Mallinckrodt (NYSE MNK)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  713 (Vote Outperform)
Underperform Votes:  481 (Vote Underperform)
Total Votes:  1,194
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel